Efficacy of Rituximab

Rituximab (Rituximab) is administered through an intravenous infusion (drip). Depending on the condition being treated, patients may also be given other medications, which are currently only available by prescription. The active ingredient in Rituximab, Rituximab, is a monoclonal antibody (a protein) designed to attach to a protein called CD20 on B lymphocytes. When rituximab attaches to CD20, it causes B lymphocytes to die, which contributes to lymphoma and CLL (B lymphocytes have become cancerous) as well as rheumatoid arthritis (B lymphocytes are involved in joint inflammation). In granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), destroying B lymphocytes reduces the production of antibodies, which are thought to play an important role in attacking blood vessels and causing inflammation.

Rituximab has been launched in China and has entered the scope of Class B medical insurance. The use of rituximab must be carried out by doctors and medical staff. It is a strictly controlled drug and its purchase and use may be restricted. SpecificationsThe price of each box of 500mg/500mL may be around RMB 8,000, which is relatively expensive. Rituximab has also been launched overseas. The price of the original Indian version of 500mg/500mL per box may be around RMB 3,000 (the price may fluctuate due to exchange rates) . There are also generic rituximab drugs produced by other pharmaceutical companies in India. The price of 500mg/500mL per box may be around 1,500 yuan (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of domestic and foreign original drugs.